Kalkine has a fully transformed New Avatar.
Last update at 2025-06-27T06:10:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Telix Reports US$186M Q1 Revenue, Up 62% YOY
Tue 22 Apr 25, 08:17 AMIPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
Tue 15 Apr 25, 10:37 PMAll You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy
Mon 14 Apr 25, 04:00 PMTelix Announces Cardinal Health for Gozellix Commercial Distribution
Tue 08 Apr 25, 10:30 AMTelix Appoints Paul Schaffer as Chief Technology Officer
Sun 06 Apr 25, 11:09 PMAnne Whitaker Appointed as Non-Executive Director
Thu 03 Apr 25, 10:13 PMARTMS Drug Master File for Gallium Production Technology Referenced with Telix’s Gozellix®
Tue 01 Apr 25, 12:49 PMFDA Approves New Prostate Cancer Imaging Agent Gozellix®
Fri 21 Mar 25, 10:30 AMBreakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | -98.62200M | -80.46500M | -47.93500M | -31.12200M | -15.71389M |
Minority interest | - | - | - | - | - |
Net income | -104.07900M | -80.51000M | -44.88700M | -27.86700M | -13.82982M |
Selling general administrative | 77.32M | 34.92M | 18.01M | 11.28M | 8.50M |
Selling and marketing expenses | 16.19M | 5.89M | 1.20M | 0.31M | 0.58M |
Gross profit | 94.43M | 2.35M | 2.66M | 0.94M | 0.20M |
Reconciled depreciation | 5.38M | 5.17M | 4.88M | 4.24M | 0.00697M |
Ebit | -92.20600M | -75.24700M | -46.76000M | -28.71400M | -15.68487M |
Ebitda | -86.82700M | -70.07300M | -41.87800M | -24.47800M | -15.67791M |
Depreciation and amortization | 5.38M | 5.17M | 4.88M | 4.24M | 0.00697M |
Non operating income net other | - | - | - | - | - |
Operating income | -92.20600M | -75.24700M | -46.76000M | -28.71400M | -27.65396M |
Other operating expenses | 251.00M | 103.70M | 54.47M | 43.74M | - |
Interest expense | 6.42M | 5.22M | 1.18M | 2.41M | 0.03M |
Tax provision | 5.46M | 0.04M | -3.04800M | -3.25500M | -1.88407M |
Interest income | 0.00100M | 0.16M | 0.07M | 2.39M | 1.80M |
Net interest income | -6.69200M | -5.21800M | -1.10800M | -2.31000M | 0.30M |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | 5.46M | 0.04M | -3.04800M | -3.25500M | -1.88407M |
Total revenue | 155.98M | 4.90M | 4.68M | 3.48M | 0.20M |
Total operating expenses | 189.44M | 101.15M | 52.44M | 41.20M | 27.85M |
Cost of revenue | 61.56M | 2.55M | 2.02M | 2.54M | 0.00000M |
Total other income expense net | -6.41600M | -5.21800M | -1.17500M | -2.40800M | 11.94M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | -104.07900M | -80.51000M | -44.88700M | -27.86700M | -13.82982M |
Net income applicable to common shares | -104.07900M | -80.51000M | -44.88700M | -27.86700M | -13.83000M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
Total assets | 1516.43M | 398.30M | 255.35M | 109.81M | 157.82M |
Intangible assets | 309.49M | 104.82M | 53.47M | 51.63M | 54.97M |
Earning assets | - | - | - | - | - |
Other current assets | - | 7.10M | 6.57M | 1.43M | 1.79M |
Total liab | 948.22M | 249.39M | 175.35M | 107.66M | 78.81M |
Total stockholder equity | 568.21M | 148.91M | 80.01M | 2.16M | 79.02M |
Deferred long term liab | - | - | - | - | - |
Other current liab | 85.91M | 123.01M | 68.11M | 6.14M | 6.29M |
Common stock | - | 446.27M | 370.97M | 170.84M | 167.06M |
Capital stock | 0.00000M | 446.27M | 370.97M | 170.84M | 167.06M |
Retained earnings | -212.96200M | -263.66500M | -272.81500M | -173.47100M | -92.96100M |
Other liab | - | - | 79.98M | 67.77M | 57.41M |
Good will | 106.65M | 4.85M | 5.52M | 4.10M | 4.22M |
Other assets | - | - | 3.97M | 0.21M | 0.18M |
Cash | 710.35M | 123.24M | 116.33M | 22.04M | 77.94M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 330.91M | 157.41M | 85.56M | 37.98M | 19.96M |
Current deferred revenue | - | 112.02M | - | 19.32M | 7.09M |
Net debt | - | -105.79200M | -105.88300M | -19.49800M | -75.73800M |
Short term debt | - | 1.56M | 0.64M | 0.63M | 0.77M |
Short long term debt | 18.99M | 0.96M | - | 0.02M | 0.26M |
Short long term debt total | - | 17.45M | 10.45M | 2.54M | 2.21M |
Other stockholder equity | - | - | -0.56200M | 4.79M | 4.92M |
Property plant equipment | - | - | 18.84M | 6.33M | 4.82M |
Total current assets | 918.56M | 224.85M | 173.23M | 47.54M | 93.63M |
Long term investments | 6.09M | 12.26M | - | - | - |
Net tangible assets | - | - | 21.02M | -53.57100M | 19.83M |
Short term investments | - | - | - | - | - |
Net receivables | 139.44M | 64.78M | 39.35M | 19.42M | 12.40M |
Long term debt | 551.82M | 8.21M | 3.31M | 0.00000M | 0.10M |
Inventory | 38.14M | 17.31M | 8.48M | 3.45M | 0.63M |
Accounts payable | 68.70M | 32.84M | 16.81M | 11.88M | 5.81M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | - | -33.69200M | -18.15000M | 4.79M | 4.92M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | - | - | - | 167.06M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | - | - | - | - |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 74.58M | 1.17M | 0.33M | 0.21M | 0.18M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 597.87M | 173.45M | 82.12M | 62.27M | 64.19M |
Capital lease obligations | 10.64M | 8.27M | 7.13M | 2.52M | 1.85M |
Long term debt total | - | - | 9.80M | 1.91M | 1.44M |
Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
Investments | -135.17300M | -25.48900M | -16.99700M | -2.72600M | -1.09100M |
Change to liabilities | - | - | 27.64M | 4.79M | 32.42M |
Total cashflows from investing activities | - | - | -16.99700M | -2.72600M | -1.09100M |
Net borrowings | - | - | 1.74M | -0.93600M | -0.90400M |
Total cash from financing activities | 638.92M | 10.19M | 174.96M | 2.85M | 34.12M |
Change to operating activities | - | - | -3.68600M | 2.60M | -0.19300M |
Net income | 49.92M | 5.21M | -104.07900M | -80.51000M | -44.88700M |
Change in cash | 587.11M | 6.91M | 94.29M | -55.90800M | 33.35M |
Begin period cash flow | 123.24M | 116.33M | 22.04M | 77.94M | 44.60M |
End period cash flow | 710.35M | 123.24M | 116.33M | 22.04M | 77.94M |
Total cash from operating activities | 43.03M | 23.88M | -63.97000M | -59.32800M | 1.96M |
Issuance of capital stock | 1.00M | 6.65M | 181.04M | 3.78M | 35.15M |
Depreciation | - | 6.92M | 5.38M | 5.17M | 4.88M |
Other cashflows from investing activities | -34.16900M | -1.17100M | -2.16300M | -1.38700M | -0.44700M |
Dividends paid | - | - | 168.41M | - | 34.49M |
Change to inventory | - | -9.63600M | -5.02300M | -2.82100M | -0.09100M |
Change to account receivables | - | -27.38200M | -19.93400M | -7.19200M | -0.32800M |
Sale purchase of stock | - | - | -7.81600M | 3.78M | -0.13000M |
Other cashflows from financing activities | -14.88400M | -2.22200M | -1.26400M | -0.59600M | -0.50200M |
Change to netincome | - | - | 35.74M | 18.64M | 10.15M |
Capital expenditures | 34.03M | 10.79M | 13.86M | 1.34M | 0.32M |
Change receivables | - | - | - | - | - |
Cash flows other operating | - | - | - | - | - |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | - | - | - | - |
Change in working capital | -64.27100M | -57.53400M | -1.00700M | -2.63000M | 31.81M |
Stock based compensation | - | 8.79M | 8.11M | 1.32M | 2.35M |
Other non cash items | 107.30M | 60.50M | 41.00M | 31.52M | 18.66M |
Free cash flow | 9.00M | 13.09M | -77.83100M | -60.66700M | 1.64M |
Sector: Healthcare Industry: Biotechnology
Company | Change (AUD) | Price (AUD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
TLX Telix Pharmaceuticals Ltd |
-0.29 1.17% | 24.44 | 177.75 | 56.82 | 10.64 | 14.57 | 10.40 | 88.05 |
CSL CSL Ltd |
-5.64 2.35% | 234.34 | 28.55 | 32.05 | 7.64 | 4.03 | 5.80 | 18.01 |
MSB Mesoblast Ltd |
0.03 1.85% | 1.65 | - | 454.55 | 369.57 | 2.90 | 67.90 | -9.8623 |
NEU Neuren Pharmaceuticals Ltd |
0.89 6.69% | 14.20 | 12.99 | 78.12 | 8.25 | 4.61 | 7.03 | 8.53 |
CU6 Clarity Pharmaceuticals Ltd |
0.13 5.44% | 2.52 | - | - | 71.29 | 5.28 | -0.7791 |
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases. The company operates through three segments: Therapeutics, Precision Medicine, and Telix Manufacturing Solutions. It offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. The company's products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX007-CDx, a cold kit for the preparation of imaging for prostate cancer; TLX66-CDx to treat bone marrow conditioning. It also TLX250 for the treatment of clear cell renal cell carcinoma; TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning. In addition, the company develops TLX300 for the treatment of soft tissue sarcoma; TLX592, a prostate cancer therapy candidate for targeted alpha therapy; and TLX090, a bone-seeking agent for bone metastases and pain palliation. Further, it operates in Australia, New Zealand, Belgium, Japan, Switzerland, Germany, the United Kingdom, Canada, Singapore, Austria, Spain, France, and the United States. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
55 Flemington Road, North Melbourne, VIC, Australia, 3051
Name | Title | Year Born |
---|---|---|
Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., MBA | Co-Founder, Group MD, CEO & Exec. Director | 1975 |
Dr. Andreas Kluge M.D., Ph.D. | Chief Medical Advisor & Director | NA |
Mr. Darren Smith B.Bus., FCPA, M.B.A. | Group Chief Financial Officer | 1965 |
Dr. Michael Wheatcroft B.Sc., BSc(Hons), Ph.D., Ph.D., (Cantab) | Chief Scientist | NA |
Ms. Kyahn Williamson | Sr. VP of Corp. Communications & Investor Relations | NA |
Ms. Melanie Farris (AGIA, ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C. | Sr. VP of Global Governance, Risk & Compliance | NA |
Ms. Lena Moran-Adams | Gen. Counsel | NA |
Ms. Amanda Griffin | Communications Mang. | NA |
Mr. Christian Davis | VP Sales and Marketing, EMEA | NA |
Ms. Meredith Crowe | Interim Sr. VP of Global People & Culture | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.